CME Group Inc. (NASDAQ:CME) Stock Holdings Increased by Trust Co. of Vermont

Trust Co. of Vermont boosted its holdings in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 5.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,896 shares of the financial services provider's stock after purchasing an additional 2,906 shares during the period. Trust Co. of Vermont's holdings in CME Group were worth $16,155,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Diversified Trust Co acquired a new stake in shares of CME Group during the 1st quarter valued at $278,000. Board of the Pension Protection Fund acquired a new stake in shares of CME Group during the first quarter worth $159,000. Perpetual Ltd lifted its holdings in shares of CME Group by 2,214.8% during the first quarter. Perpetual Ltd now owns 277,434 shares of the financial services provider's stock valued at $73,600,000 after purchasing an additional 265,449 shares during the last quarter. PDS Planning Inc lifted its holdings in shares of CME Group by 11.2% during the first quarter. PDS Planning Inc now owns 2,802 shares of the financial services provider's stock valued at $743,000 after purchasing an additional 282 shares during the last quarter. Finally, Balefire LLC boosted its position in shares of CME Group by 5.9% in the 1st quarter. Balefire LLC now owns 1,625 shares of the financial services provider's stock valued at $431,000 after purchasing an additional 91 shares during the period. 87.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CME Group

In related news, Director Dennis Suskind sold 1,000 shares of CME Group stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $271.28, for a total transaction of $271,280.00. Following the sale, the director now directly owns 2,915 shares of the company's stock, valued at $790,781.20. This trade represents a 25.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel G. Kaye sold 500 shares of the business's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $282.42, for a total value of $141,210.00. Following the transaction, the director now owns 3,668 shares in the company, valued at $1,035,916.56. This represents a 12.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,400 shares of company stock worth $3,680,610 over the last three months. Corporate insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on CME shares. JPMorgan Chase & Co. reduced their price objective on shares of CME Group from $223.00 to $211.00 and set an "underweight" rating for the company in a research note on Thursday, April 24th. Keefe, Bruyette & Woods boosted their price target on shares of CME Group from $265.00 to $273.00 and gave the company a "market perform" rating in a report on Thursday, April 24th. Barclays raised their price objective on shares of CME Group from $279.00 to $283.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 23rd. Bank of America lifted their price objective on shares of CME Group from $200.00 to $219.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 2nd. Finally, Royal Bank Of Canada reissued a "sector perform" rating and set a $269.00 target price on shares of CME Group in a research note on Thursday, April 3rd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, CME Group presently has an average rating of "Hold" and an average target price of $258.20.

CME Group Trading Down 0.1%

Shares of NASDAQ CME opened at $272.83 on Friday. The business has a 50 day simple moving average of $274.96 and a 200 day simple moving average of $256.28. CME Group Inc. has a 52 week low of $193.17 and a 52 week high of $290.79. The stock has a market cap of $98.32 billion, a price-to-earnings ratio of 27.45, a PEG ratio of 3.70 and a beta of 0.45. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02.

CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.61 by $0.19. The company had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. CME Group had a net margin of 57.71% and a return on equity of 14.03%. CME Group's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.50 EPS. On average, research analysts predict that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th were given a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a yield of 1.83%. The ex-dividend date was Monday, June 9th. CME Group's payout ratio is 50.30%.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.